The Bridging study of RNTA06, which is indicated for the treatment of chronic angina, is completed and unblended

2019/06/26

TSH Biopharm Co., Ltd. (8432) announced today (6/26) that the Bridging study of RNTA06, which is indicated for the treatment of chronic angina, is completed and unblended, and the result meets the primary endpoint.

This compound has been launched in other countries with comprehensive foreign clinical trial data. However, there is no sufficient clinical data to demonstrate the efficacy in Asia patient population.

This double-blind design study is to demonstrate RNTA06 can be extrapolated to Taiwan patient population based on the data in pharmacokinetic/pharmacodynamics, efficacy, and safety. The result of this study indicates high similar trend with the global study in Taiwanese population.

There are about 550,000 patients with angina in Taiwan, and around 30% of them cannot be relieved after the treatment of current medication. RNTA06 is identified as an NCE in Taiwan and is indicated for the treatment of chronic angina with new mechanism as late sodium channel inhibitor.

There is no significant data indicate RNTA06 will affect heart rate, blood pressure, and side effects of headache. RNTA06 can be considered as the medication combination with current treatment or an alternative choice. TSH Biopharm will submit RNTA06 to TFDA for Marketing Approval shortly.